Search Results for: DNA VACCINES MARKET DNA Vaccines
Articles
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate March 31, 2022
AGC Biologics recently announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The...Catalent Biologics Completes $30-Million Project for Biopharmaceutical Development & Drug Product Manufacturing in Limoges, France March 16, 2022
Catalent recently announced the completion of a $30-million project at its facility in Limoges, France, to transform the site into...SPECIAL FEATURE - Solubility & Bioavailability: Utilizing Enabling Technologies March 1, 2022
Contributor Cindy H. Dubin interviews several leading companies on how they are using innovative technologies, such as lipid nanoparticles to achieve a high drug loading, combining anti-solvent continuous crystallization with micro-mixing technology to control crystallization and reduce crystal size, and how a robotic capsule can improve bioavailability in the range of 47% to 78%.
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase 2 Portion of the OVATION 2 Study With GEN-1 in Advanced Ovarian Cancer February 17, 2022
Celsion Corporation recently announced that following a pre-planned interim safety review of 81 as treated patients randomized in the Phase 1/2 OVATION 2 Study with….
WACKER & CordenPharma Develop Solutions for Formulating Lipid Nanoparticles, Expanding Their Portfolio for Advanced Medicines December 14, 2021
WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced they...Dyadic Announces Technology Transfer & Licensing Agreement With South Africa’s Rubic Consortium July 28, 2021
Dyadic International, Inc. recently announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a...Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe July 21, 2021
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions...2021 Respiratory Drug Development eBook – The Three Cs Driving Respiratory Drug Delivery June 29, 2021
In this third annual Drug Development & Delivery Respiratory eBook, several companies discuss what they are currently working on to propel the respiratory sector.
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Toward Industrialization of Induced Pluripotent Stem Cell-Based Therapies June 29, 2021
Catalent recently announced it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs)…..
AavantiBio & Catalent Announce Partnership to Support Development & Manufacturing of Gene Therapies April 29, 2021
AavantiBio and Catalent recently announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA)….
Catalent Biologics Completes Madison Facility Expansion to Double Clinical & Commercial Drug Substance Capacity April 14, 2021
Catalent recently announced it has completed the expansion of two new suites at its biologics drug substance development and manufacturing...CELL & GENE THERAPY - End-to-End Cell & Gene Therapy – From Development to Commercialization – Buy or Build? March 1, 2021
Aldo Romano and Emily Moran, MBA, discuss how the life science industry must bring technology solutions to the table while at the same time securing the capacity to develop and manufacture groundbreaking cures so patients and society can tap the benefits of cell and gene therapies.
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer February 24, 2021
Celsion Corporation recently announced that it has received Fast Track designation from the US FDA for GEN-1, its DNA-mediated interleukin-12...PLATFORM TECHNOLOGY - Morphomer(TM) & SupraAntigen(TM) Platforms: Targeting Misfolded Proteins in Neurodegenerative Disorders October 1, 2020
Andrea Pfeifer, PhD, details the efforts to develop the therapeutic and diagnostic tools necessary to enable precision medicine approaches targeting the right protein, at the right time, in the right patient.
GENE THERAPY - The Role Viral Vectors Play in Current Gene Therapy Development June 4, 2020
Dieter Lingelbach, MBA, discusses the history and science of viral vectors, their current applications, and why they are a vital component in contemporary gene therapy development.
N4 Pharma Provides Covid-19 Project & Operational Update April 3, 2020
N4 Pharma Plc, the specialist pharmaceutical company developing Nuvec, a novel delivery system for cancer treatments and vaccines, recently announced...Novavax’s NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial March 25, 2020
Novavax, Inc. recently announced positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu, its recombinant quadrivalent seasonal...INTRATUMORAL DELIVERY - Arming the Immune System; Turning Cold Tumors Hot August 29, 2019
Daniel J. O’Connor believes a trigger mechanism that can turn cold tumors hot can help researchers set their focus on delivering potentially life-saving drugs directly to core of a cancerous tumor.
Amicus Therapeutics & Catalent Biologics Enter Strategic Partnership July 2, 2019
Amicus Therapeutics, Inc. has entered into a strategic manufacturing agreement with Paragon Gene Therapy, a unit of Catalent Biologics, for clinical manufacturing capabilities and capacity for….
Novavax & Catalent Biologics Enter Strategic Partnership June 26, 2019
Novavax, Inc. and Catalent Biologics’ Paragon Gene Therapy unit recently announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to……..
